OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis
Min Wang, Zhaohui Huang, Xin Li, et al.
Pharmacological Research (2024) Vol. 207, pp. 107306-107306
Open Access | Times Cited: 5
Min Wang, Zhaohui Huang, Xin Li, et al.
Pharmacological Research (2024) Vol. 207, pp. 107306-107306
Open Access | Times Cited: 5
Showing 5 citing articles:
Polo‐like kinase2 regulates renal tubulointerstitial fibrosis via notch signaling pathway in diabetic kidney disease
Jiayi Luo, Haibin Xu, Cailin Su, et al.
The FASEB Journal (2025) Vol. 39, Iss. 5
Open Access | Times Cited: 1
Jiayi Luo, Haibin Xu, Cailin Su, et al.
The FASEB Journal (2025) Vol. 39, Iss. 5
Open Access | Times Cited: 1
BRD4: an effective target for organ fibrosis
Qun Wei, Cailing Gan, Meng Sun, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Qun Wei, Cailing Gan, Meng Sun, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
The Bromodomain and extra-terminal Protein Inhibitor Apabetalone ameliorates kidney injury in diabetes by regulating cholesterol accumulation and modulating the gut microbiota
Min Wang, Zhaohui Huang, Yonghong Zhu, et al.
Kidney International Reports (2024)
Open Access | Times Cited: 1
Min Wang, Zhaohui Huang, Yonghong Zhu, et al.
Kidney International Reports (2024)
Open Access | Times Cited: 1
Exploring the Therapeutic Potential of Apabetalone in Diabetic Kidney Disease: Bridging Preclinical Findings with Clinical Translation
Honglian Luo, Yi Yao, Wenhua Wang, et al.
Pharmacological Research (2024) Vol. 208, pp. 107362-107362
Open Access
Honglian Luo, Yi Yao, Wenhua Wang, et al.
Pharmacological Research (2024) Vol. 208, pp. 107362-107362
Open Access
Commentary on “Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis”
Kaiqing Li, Xue Xia, Tong Fu, et al.
Pharmacological Research (2024) Vol. 209, pp. 107329-107329
Open Access
Kaiqing Li, Xue Xia, Tong Fu, et al.
Pharmacological Research (2024) Vol. 209, pp. 107329-107329
Open Access
